COX-2 Overexpression in Schneiderian Papillomas
Background Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. Objective evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. Methods Immunohistochemistry for COX-2 was performed on SP samples and middl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-12-01
|
| Series: | Allergy & Rhinology |
| Online Access: | https://doi.org/10.1177/2152656720973689 |
| _version_ | 1818730359395713024 |
|---|---|
| author | Jeffrey D. Suh MD Kevin Hur MD Elisabeth H. Ference MD, MPH David D. Lam BS Andrew Fong MD Adrian J. Correa MD Bozena Wrobel MD |
| author_facet | Jeffrey D. Suh MD Kevin Hur MD Elisabeth H. Ference MD, MPH David D. Lam BS Andrew Fong MD Adrian J. Correa MD Bozena Wrobel MD |
| author_sort | Jeffrey D. Suh MD |
| collection | DOAJ |
| description | Background Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. Objective evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. Methods Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009–2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA. Results The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples. Conclusion COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme. |
| first_indexed | 2024-12-17T23:00:32Z |
| format | Article |
| id | doaj.art-cad3653ea9bf42f08dbc42c2bfa8cafb |
| institution | Directory Open Access Journal |
| issn | 2152-6567 |
| language | English |
| last_indexed | 2024-12-17T23:00:32Z |
| publishDate | 2020-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Allergy & Rhinology |
| spelling | doaj.art-cad3653ea9bf42f08dbc42c2bfa8cafb2022-12-21T21:29:25ZengSAGE PublishingAllergy & Rhinology2152-65672020-12-011110.1177/2152656720973689COX-2 Overexpression in Schneiderian PapillomasJeffrey D. Suh MDKevin Hur MDElisabeth H. Ference MD, MPHDavid D. Lam BSAndrew Fong MDAdrian J. Correa MDBozena Wrobel MDBackground Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. Objective evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. Methods Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009–2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA. Results The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples. Conclusion COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.https://doi.org/10.1177/2152656720973689 |
| spellingShingle | Jeffrey D. Suh MD Kevin Hur MD Elisabeth H. Ference MD, MPH David D. Lam BS Andrew Fong MD Adrian J. Correa MD Bozena Wrobel MD COX-2 Overexpression in Schneiderian Papillomas Allergy & Rhinology |
| title | COX-2 Overexpression in Schneiderian Papillomas |
| title_full | COX-2 Overexpression in Schneiderian Papillomas |
| title_fullStr | COX-2 Overexpression in Schneiderian Papillomas |
| title_full_unstemmed | COX-2 Overexpression in Schneiderian Papillomas |
| title_short | COX-2 Overexpression in Schneiderian Papillomas |
| title_sort | cox 2 overexpression in schneiderian papillomas |
| url | https://doi.org/10.1177/2152656720973689 |
| work_keys_str_mv | AT jeffreydsuhmd cox2overexpressioninschneiderianpapillomas AT kevinhurmd cox2overexpressioninschneiderianpapillomas AT elisabethhferencemdmph cox2overexpressioninschneiderianpapillomas AT daviddlambs cox2overexpressioninschneiderianpapillomas AT andrewfongmd cox2overexpressioninschneiderianpapillomas AT adrianjcorreamd cox2overexpressioninschneiderianpapillomas AT bozenawrobelmd cox2overexpressioninschneiderianpapillomas |